FindTrial
Sign In

ASTX660

DRUG6 trials

Sponsors

Taiho Oncology, Inc., Astex Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Institute of Cancer Research, United Kingdom

Conditions

Acute Myeloid LeukemiaAdvanced CancerCervical CancerHealthy VolunteerLymphomaRelapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)Solid TumorsTriple Negative Breast Cancer

Phase 1

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Active, not recruitingNCT02503423
Taiho Oncology, Inc.Lymphoma, Solid Tumors
Start: 2015-07-14End: 2027-12-01Updated: 2026-03-20
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
TerminatedNCT04155580
Astex Pharmaceuticals, Inc.Acute Myeloid Leukemia
Start: 2020-06-12End: 2022-01-14Updated: 2024-08-02
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
TerminatedNCT04362007
Otsuka Pharmaceutical Co., Ltd.Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
Start: 2020-07-14End: 2024-11-30Updated: 2026-02-25
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
CompletedNCT04411030
Astex Pharmaceuticals, Inc.Healthy Volunteer
Start: 2020-05-20End: 2020-08-29Updated: 2024-08-02
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
CompletedNCT04479800
Astex Pharmaceuticals, Inc.Healthy Volunteer
Start: 2020-07-20End: 2020-08-25Updated: 2024-08-02
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Active, not recruitingNCT05082259
Institute of Cancer Research, United KingdomAdvanced Cancer, Cervical Cancer, Triple Negative Breast Cancer
Start: 2022-03-02End: 2026-12-01Target: 61Updated: 2026-06-25

Related Papers

Translational investigation of tolinapant (ASTX660) in Acute Myeloid Leukemia using integrated clinical, bioinformatic, and pharmacological approaches
Blood2025-11-03
Epigenetic Priming By Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-Cell Lymphoma
Blood2023-11-022 citations
ASTX660-01 Phase 2: A Case Study of Tolinapant-Induced Pseudoprogression in CTCL
Blood2023-11-021 citations
Tolinapant, a Non-Peptidomimetic Antagonist of Inhibitors of Apoptosis Proteins, cIAP1/2 and XIAP, in Combination with the Hypomethylating Agents, Azacytidine and Decitabine Are Highly Synergistic in <i>in Vitro</i> Models of T Cell Lymphoma
Blood2022-11-151 citations
Abstract 5337: Tolinapant (ASTX660) enhances the anti-leukemic activity of Venetoclax and Dexamethasone in T cell acute lymphoblastic leukemia (T-ALL)
Cancer Research2022-06-151 citations
S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE.
HemaSphere2022-06-012 citations
P1293: COMBINING THE IAP ANTAGONIST, TOLINAPANT, WITH A DNA HYPOMETHYLATING AGENT ENHANCES ANTI-TUMOUR MECHANISMS IN PRECLINICAL MODELS OF T-CELL LYMPHOMA.
HemaSphere2022-06-01
P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-CELL LYMPHOMA (TCL).
HemaSphere2022-06-01
The combination of the IAP antagonist, tolinapant and hypomethylating agents (HMA) is highly synergistic in <i>in vitro</i> models of T-cell lymphoma (TCL).
Journal of Clinical Oncology2022-06-01
Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma
Blood2021-11-051 citations
Tolinapant (ASTX660), a Non-Peptidomimetic Antagonist of cIAP1/2 and XIAP, and the HDAC Inhibitor Romidepsin Are Synergistic in <i>in Vitro</i> Models of T Cell Lymphoma
Blood2021-11-05
Abstract PO-12: Activity of ASTX660, a small-molecule IAP antagonist, reveals a novel, immune-based therapeutic approach in T-cell lymphoma
Blood Cancer Discovery2020-11-01
Abstract 5542: ASTX660, a non-peptidomimetic antagonist of cIAP1/2 and XIAP, enhances immune mediated tumor killing and induction of immunogenic cell death
Cancer Research2020-08-151 citations
Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma
Molecular Cancer Therapeutics2019-12-012 citations
PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA
HemaSphere2019-06-015 citations
PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA
Hematological Oncology2019-06-014 citations
PS1322 ASTX660, A NON‐PEPTIDOMIMETIC ANTAGONIST OF CIAP1/2 AND XIAP, INDUCES APOPTOSIS IN T CELL LYMPHOMA BY ENHANCING IMMUNE MEDIATED AND DEATH RECEPTOR DEPENDENT KILLING
HemaSphere2019-06-01
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 <i>H</i> ,2 <i>H</i> ,3 <i>H</i> -pyrrolo[3,2- <i>b</i> ]pyridin-1-yl)-2-[(2 <i>R</i> ,5 <i>R</i> )-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)
Journal of Medicinal Chemistry2018-08-0951 citations
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Molecular Cancer Therapeutics2018-04-2572 citations
Abstract A091: Phase 1 study of IAP inhibitor ASTX660 in adults with advanced cancers and lymphomas
Molecular Cancer Therapeutics2018-01-015 citations

2 more papers not shown